Cargando…
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
Autor principal: | Kuykendall, Andrew T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261220/ https://www.ncbi.nlm.nih.gov/pubmed/37088817 http://dx.doi.org/10.1007/s00277-023-05235-0 |
Ejemplares similares
-
Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023) -
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020) -
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
por: Alvarez‐Larrán, Alberto, et al.
Publicado: (2022) -
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023) -
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)